Natco Pharma Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Natco Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 1479.3, up 2.32% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 1.01% on the day, quoting at 23954.849609375. The Sensex is at 79251.13, down 1.16%. Natco Pharma Ltd has gained around 7.61% in last one month.

Meanwhile, Nifty Pharma index of which Natco Pharma Ltd is a constituent, has gained around 4.06% in last one month and is currently quoting at 22314.55, up 1.38% on the day. The volume in the stock stood at 9.96 lakh shares today, compared to the daily average of 6.58 lakh shares in last one month.

The PE of the stock is 14.09 based on TTM earnings ending September 24.

Powered by Capital Market - Live News

Natco Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 1429.95, up 1.05% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.63% on the day, quoting at 24428.3. The Sensex is at 80776.82, up 0.66%. Natco Pharma Ltd has added around 1.49% in last one month.

Meanwhile, Nifty Pharma index of which Natco Pharma Ltd is a constituent, has added around 0.61% in last one month and is currently quoting at 22450.2, up 0.22% on the day. The volume in the stock stood at 7.85 lakh shares today, compared to the daily average of 7.49 lakh shares in last one month.

The PE of the stock is 13.78 based on TTM earnings ending September 24.

Powered by Capital Market - Live News

The drug maker stated that since no business operations are carried out on the said land and building being sold, the sale will not have any impact on the business operations of the company.

Further, the sale of the said property does not constitute an undertaking or substantially the whole of the undertaking for the company in terms of Section 180(1)(a) of the Companies Act, 2013.

Natco Pharma is engaged in the business of pharmaceuticals which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The company has manufacturing facilities in India, which cater to both domestic and international markets, including regulated markets like the United States of America and Europe.

The company’s consolidated net profit surged 83.55% to Rs 677.30 crore on a 32.93% increase in revenue from operations to Rs 1,371.1 crore in Q2 FY25 over Q2 FY24.

The scrip rose 0.11% to currently trade at Rs 1,362.65 on the BSE.

Powered by Capital Market - Live News

Natco Pharma today announced submission of Abbreviated New Drug Application (ANDA) with USFDA  for Risdiplam for Oral Solution.

NATCO believes it is amongst one of the first two companies to have filed a substantially-complete ANDA containing a paragraph IV certification for this product and expects to be eligible for 180 days of shared marketing exclusivity at the time of potential launch of the generic product under certain circumstances. NATCO has been named as one of the defendants in a lawsuit filed in the United States District Court for the District of New Jersey by Genentech, Inc., Hoffmann-La Roche Inc., and PTC Therapeutics, Inc.

EVRYSDI® has recorded sales of USD 571 million in the US market for the year 2023.

Risdiplam for Oral Solution is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Powered by Capital Market - Live News